A phase 2, multicenter, placebo-controlled study of single-dose squaric acid dibutyl ester to reduce frequency of outbreaks in patients with recurrent herpes labialis - 15/09/20

Anne Lynn S. Chang, MD ^a, Golara Honari, MD ^a, Linna Guan, MD ^a, Ludan Zhao, MD, PhD ^a, Maria Alora Palli, MD ^{b, c}, Thomas D. Horn, MD ^{b, c, d}, Arkadiusz Z. Dudek, MD, PhD ^d, Hugh McTavish, PhD ^{d, ⁎}

^a Department of Dermatology, Stanford University School of Medicine, Redwood City, California 

^b Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts 

^c Harvard Medical School, Boston, Massachusetts 

^d Squarex, LLC, Pine Springs, Minnesota 

^∗Correspondence to: Hugh McTavish, PhD, Department of Dermatology, Stanford University School of Medicine, Discovery Hall, Rm 143, Mail Code 8843, 455 Broadway St, Redwood City, CA 94063Department of DermatologyStanford University School of MedicineDiscovery Hall, Rm 143, Mail Code 8843, 455 Broadway StRedwood CityCA94063